Bayer Advanced Aspirin (aspirin fast release) / Bayer - LARVOL DELTA

Comparison of gastrointestinal adverse events between fast release tablets and regular acetylsalicylic acid (aspirin) galenics after short-term use: a meta-analysis of randomized clinical trials. (PubMed, Inflammopharmacology) - "In conclusion, aspirin FR tablets showed a comparable GI tolerability to regular galenic formulations of aspirin after short-term treatment. Major GI complication did not occur after intake of any galenic formulation of aspirin."

Adverse events • Clinical • Journal • Retrospective data • Gastrointestinal Disorder

Ticagrelor with aspirin or alone in high-risk patients after coronary intervention: Rationale and design of the TWILIGHT study (Am Heart J) - KOL: Michael Gibson; P4, N=9,000; TWILIGHT (NCT02270242); "TWILIGHT is the largest study to date that is specifically designed and powered to demonstrate reductions in bleeding with ticagrelor monotherapy versus ticagrelor plus ASA beyond 3 months post-procedure in a high-risk PCI population treated with DES. The trial will provide novel insights with respect to the potential role of ticagrelor monotherapy as an alternative for long-term platelet inhibition in a broad population of patients undergoing PCI with DES."

P4 data • Cardiovascular

Mille: Bioequivalence of Single Dose Fast Release Aspirin (1000 mg) Tablet Versus Single Dose of Two 500 mg Fast Release Aspirin Tablets (clinicaltrials.gov) - P1; N=38; Completed; Sponsor: Bayer

New P1 trial • Biosimilar • Pain

Frequency and severity of reactions to a 325-mg aspirin dose during desensitization (Ann Allergy Asthma Immunol) - P=NA, N=104; "One initial provoking reaction to 325 mg occurred. Both 325-mg reactions were mild, and neither met the forced expiratory volume in 1 second criterion for a clinically meaningful change. The remaining 5 patients could not complete the protocol because of persistent reactions or social reasons. Reactors were more likely to have had asthma for more than 10 years than nonreactors (odds ratio, 3.2; 95% confidence interval, 1.0-10.3; P = .05)."

Clinical data • Asthma